Keep this stock on your watch list.
Here's what to avoid for now.
Let's check out the charts and indicators of both NovoCure and Zai Lab.
The oncology company's stock has been correcting sideways for a few months but seems poised for renewed gains.
The charts are indicating that the stock's downward trend for much of the last year may be ending.
The charts of the oncology company are nothing but bearish and its stock could be in for more downside action ahead.
The stock of the provider of genetic analysis products is pulling back more than expected, so here's what may be next.
The maker of life science research and clinical diagnostic products could trade sideways for awhile before a sustained advance begins.
The stock bottomed in June/July and have worked higher.
Will we see a move from aggressive selling to aggressive buying?